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CT group NCT group p-value
No. of patients 409 214
Age (mean) Range in years 67 (35-85) 70 (46-86) p<0.01
Age groups
30-49 18 (5%) 9 (4%) p<0.01
50-69 237 (59%) 89 (42%)
70- 154 (37%) 116 (54%)
Gender
Female 196 (48%) 102 (48%) p=0.61
Male 213 (52%) 112 (52%)
Charlson
Comorbidity Index
0 177 (43%) 90 (42%) p=0.33
1 – 2 151 (37%) 71 (33%)
>= 3 81 (20%) 53 (24%)
Type of resection
Whipple 291 (71%) 147 (69%) p=0.69
Total 67 (16%) 41 (19%)
Distal 51 (12%) 26 (12%)
Vein resection
No 339 (83%) 178 (83%) p=0.93
Yes 70 (17%) 36 (17%)
T-stage
T1 14 (3%) 12 (6%) p=0.18
T2 53 (13%) 23 (11%)
T3 322 (79%) 160 (75%)
T4 15 (4%) 13 (6%)
Missing 5 (1%) 6 (3%)
N-stage
N0 119 (29%) 71 (33%) p=0.33
N1 280 (68%) 135 (63%)
Missing 10 (2%) 8 (4%)
AJCC/UICC 
Ia 12 (3%) 9 (4%) p=0.43
Ib 26 (6%) 13 (6%)
Iia 81 (20%) 46 (22%)
Iib 266 (65%) 125 (58%)
III 15 (4%) 13 (6%)
Missing 9 (2%) 8 (4%)
• Patients in the CT group were 
significantly younger than patients in the 
NCT group (p<0.001) (Table 1).
• No difference between the groups 
regarding gender, comorbidity, type of 
resection, vein resection or T/N/AJCC 
stage were found (Table 1).
Table 1: Data on patients receiving postoperative gemcitabine within 10 
weeks after resection (CT group) or not (NCT group)
T-stage: Tumor stage, N-stage: Lymph node stage, AJCC/UICC: 7th 
edition.
Figure 1: Kaplan-Meier survival curves showing OS for all patients (top 
figure) and the subgroup of patients with lymph node metastases (bottom 
figure) according to postoperative gemcitabine (CT group) and no 
postoperative chemotherapy (NCT group) within 10 weeks after resection
Table 2: mOS according to postoperative gemcitabine (CT group) and no 
postoperative chemotherapy (NCT group) within 10 weeks after resection in all 
patients and in the subgroup of patients with lymph node metastases, as well as 5-
year survival rate for all patients (95% CI)
• No significant differences in mOS and 5-year 
survival between the patients in the CT and 
NCT group were found (Table 2 and Figure 1).
CONCLUSION
In the national Danish cohort of patients with resected PC between 2011 and 2016, the 66% receiving postoperative 
gemcitabine had a mOS of 24 months and a 5-year survival rate of 22%, which are comparable to the adjuvant 
gemcitabine arms reported in the RCTs. The subgroup of patients with lymph node metastases treated with 
postoperative gemcitabine showed significantly better mOS than those not treated.
• All patients with a curative resection in Denmark between 2011 and 2016 were identified in the Danish Pancreatic Cancer Database (DPCD). 
• Data regarding age, gender, comorbidity, type of resection, vein resection, T/N/AJCC stage (Table 1), chemotherapy and clinical follow up 
were retrieved. 
• 731 patients with ductal adenocarcinoma were treated with a curative PC resection. 
• 108 patients were excluded: 30 patients died within 10 weeks postoperatively, 29 patients were treated with other regimens than gemcitabine 
and 49 patients were treated with preoperative chemotherapy. 
• Of the remaining 623 patients, 409 (66%) received gemcitabine within 10 weeks after resection, the chemotherapy (CT) group, whereas 214 
did not receive CT within 10 weeks, the none-chemotherapy (NCT) group (Table 2).
To examine the effect of postoperative gemcitabine treatment on mOS in an unselected national cohort of patients with PC in Denmark 
during a five year period.
BACKGROUND
In Denmark, approximately 150 patients with pancreatic cancer (PC) undergo curative resection each year. Standard treatment is adjuvant 
gemcitabine. Randomised clinical trials (RCTs) using gemcitabine have shown a median overall survival (mOS) of 2 years and a 5-year survival 
rate of 15-20%. The effect of gemcitabine treatment outside trials is less clear. 
AIM
PATIENTS AND METHODS
RESULTS
n=623
Resected PC 
patients 
2011-2016
NCTCT
Treatment 
within 10 
weeks from 
resection
Clinical follow up
n= 214
22 (16-26)
26 ( 19-34)
n = 409
24 (21-27)
22 (17-27)
All patients
mOS (months)
5-year 
survival rate (%)
n=135
14 (11-17)
n=280
20 (18-24)
Subgroup with 
lymph node 
metastases 
mOS (months)
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• Patients with lymph node metastases 
showed a significantly better survival for 
the CT group with a mOS of 20 months 
versus 14 months in the NCT group 
(p=0.01) (Table 2 and Figure 1).
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